Sarepta stock surges more than 20% as FDA OKs muscular dystrophy drug
Sarepta Therapeutics Inc. SRPT, -0.97% shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Administration approved its muscular dystrophy treatment. Sarepta shares rallied 23% after hours before being halted, and were last up 28% after being unhalted. Shares closed the regular session down 1% at $100.47. The company said the FDA approved Vyondys 53 for the treatment of Duchenne muscular dystrophy.
#div-gpt-ad-1569967089584-0 > div > iframe { width: 100% !important; min-width: 300px; max-width: 800px; }
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The ultimate Disney packing list: 20 things you need for a magical vacationPortable phone charger, sunglasses, and SNACKS! What else would you add to this list, Disney fans?
Read more »
20 Baby Girl Middle NamesChoosing the perfect middle name for a baby girl can be hard -- here are some ideas.
Read more »
20 Little Known 'Christmas Vacation' Facts for Griswold Fans'National Lampoon's Christmas Vacation' will forever be a classic.
Read more »
New Zealand cuts 2019/20 GDP growth forecast, unveils capital spending boostNew Zealand cut its growth forecast for 2019/2020 and flagged a budget deficit o...
Read more »
Improve Your Balance And Build Strength With This 20-Minute Plank WorkoutThis 20-minute bodyweight workout focuses on training one side of your body at a time in order to build strength evenly on both sides of your body.
Read more »
The Top 20 TV Couples of the DecadePucker up, TV fans because we're about to kiss 2019 goodbye with a salute to the 20 best small-screen couples of the decade!
Read more »